BD (NYSE:BDX) announced today that its board of directors approved the planed spinoff of its diabetes care business, embecta.
Franklin Lakes, N.J.-based BD confirmed in May 2021 that it planned to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022 and in December 2021 it confirmed the naming of the new business as “embecta” (Embecta Corp.).
Get the full story at our sister site, Drug Delivery Business News.